News Daily News Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD Lucy Hicks February 15, 2019
News Daily News Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests Michael O'Riordan February 08, 2019
News Daily News Intensive BP Lowering May Have Cognitive Benefits: SPRINT MIND Todd Neale February 04, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019
News Daily News Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests Todd Neale February 01, 2019
News Daily News AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline Michael O'Riordan January 29, 2019
News Daily News Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis Caitlin E. Cox January 24, 2019
News Daily News Flu Tied to Worse Outcomes in Patients Hospitalized With Heart Failure Todd Neale January 03, 2019
News Daily News New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration L.A. McKeown December 18, 2018
News Daily News European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs Shelley Wood December 18, 2018
News Daily News Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention Michael O'Riordan December 10, 2018
News Conference News WCC 2018 CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden Todd Neale December 06, 2018
News Daily News Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests Michael O'Riordan December 03, 2018
News Daily News Aspirin Should Play Limited Role in Primary Prevention: Review Michael O'Riordan November 27, 2018
News Daily News Certain Risk Factors Carry Higher MI Risk in Women Than in Men Shelley Wood November 23, 2018
News Daily News Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts Michael O'Riordan November 23, 2018
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018